<DOC>
	<DOC>NCT00260962</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy of an anti-psychotic medication, Olanzapine, in achieving desired weight gain in patients identified as having Anorexia Nervosa, either restricting or binge/purge subtype. The study will also evaluate the possible beneficial effects of Olanzapine in reducing the severity of the obsessive and/or anxiety symptoms associated with this disorder.</brief_summary>
	<brief_title>Olanzapine in the Treatment of Patients With Anorexia Nervosa</brief_title>
	<detailed_description>The purpose of the study is to evaluate the efficacy of an anti-psychotic medication, Olanzapine, in achieving desired weight gain in patients identified as having Anorexia Nervosa, either restricting or binge/purge subtype. The study will also evaluate the possible beneficial effects of Olanzapine in reducing the severity of the obsessive and/or anxiety symptoms associated with this disorder.</detailed_description>
	<mesh_term>Anorexia Nervosa</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>those who meet DSM IV criteria of Anorexia Nervosa either restricting or binge/purge subtype patients who are actively self destructive and/or suicidal patients whose medical status is seriously compromised patients whose eating disorder is superimposed on a major psychiatric disorder such as schizophrenia, major affective disorders, dissociative disorder or an active substance abuse disorder.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Pilot Project,</keyword>
	<keyword>Clinical Trial,</keyword>
	<keyword>Treatment Outcome,</keyword>
	<keyword>Psychopharmacology</keyword>
</DOC>